The above facts and statistics suggest early diagnosis as a revolutionary step towards delivering quality life and increase life expectancy, in turn, improving the social, economic and physical status of older populations. The current diagnostic methods used for detection of Alzheimer disease is invasive, expensive and time-consuming although early intervention and detection are seen as imperative for controlling the disease. It takes nearly two years for evaluation of patients with Alzheimer disease and one more year to make a clear diagnosis. Till the diagnosis of Alzheimer is done, nearly 40-50% of brain function lost.
One of the major objectives of policies, regulatory guidelines, and scientific funding is to merge technological innovation with scientific research in order to answer different challenges pose by societal ageing. The stand remains same and strong in the case of Alzheimer disease. The question of the hour is – Why Alzheimer disease? The prevalence cost of treatment and future predictions implicate towards early diagnosis and simplified yet clinically relevant therapeutic approaches.
BIRAC and CEFIPRA:Indo French Centre for the Promotion of Advanced Research to support Indian and French biotech start-ups in both the countries. http://www.birac.nic.in. Supporting our Alzheimer’s Biosensor Research.
Therefore, the above situation warrants for a robust, specific and sensitive diagnostic technology that will help in early diagnosis of Alzheimer disease. The point of care diagnostic technologies is the most preferred one as compared to conventional technology which is very expensive. The high cost associated with this technology demands development of point of care diagnostic technology. The disease target population belongs to 65 years and older individuals. With ageing, the natural mobility and health condition reduces over a period of time. The objective of the scientific or clinical research is to mitigate the pain and improve the experience of patients in the context of the care process. The point of care in relation to Alzheimer disease can be specific to inequality or disparities in care.
The research both in academics and clinical scenario in the context of the point of care diagnosis is limited to infectious disease, diabetes monitoring, and other global health outbreaks. The integration of micro fluidics and other smart technologies will help in the development of point of care diagnostic for Alzheimer disease. Another advantage of development and use of such platform in Alzheimer domain is to reduce the cost of diagnosis and improve the outcomes of the patient.
Worldwide, 44 million people are affected by Alzheimer disease the situation is much worse in the context of diagnosis as only 1 out of every 4 Alzheimer patients get diagnosed with the condition. Alzheimer is one of the leading causes of the decrease in quality of life at old age as per Alzheimer international report. In US alone the cost of Alzheimer disease care cost about $236 billion per year. The global cost of Alzheimer disease caring was reported to be $ 605 billion that is equivalent to 1% of GDP of the world.
Trans-Integra looks towards the development of point of care platform for Alzheimer disease in order to facilitate diagnostic technology at low cost to all classes of the society. We would like to collaborate with organizations, NGO’s and other research organizations looking towards interdisciplinary collaboration through commensal approach. There are many small scale innovative technologies being developed in the lab and have preliminary promising data. Such projects need more funding and support from investors.
Trans-Integra hopes to take forward this approach one step forward giving a corporate social touch and improving the quality of life through the development of Point of care diagnostic technology.